Access cutting-edge essential thrombocythemia treatment through this clinical trial at a research site in Aurora. Study-provided care at no cost to qualified participants.
Access essential thrombocythemia specialists in Aurora at no cost
This study follows strict safety protocols and ethical guidelines
All study-related essential thrombocythemia treatment provided free
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this essential thrombocythemia clinical trial in Aurora, CO
If you're searching for essential thrombocythemia treatment options in Aurora, CO, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Aurora research site is actively enrolling participants for this clinical trial. You'll receive care from experienced essential thrombocythemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.